Ionis Pharmaceuticals Soars with Blockbuster Drugs

Ionis Pharmaceuticals started the year strong with impressive sales from their drugs Trangolza and Donzara, which generated over $43 million in the first quarter. Both drugs are expanding internationally with partners Sobi and Otsuka. The demand for these medications is high, and doctors appreciate their profiles, including easy self-injection and significant triglyceride reduction. Ionis is preparing for two more solo launches this year, ozarsen and zilgarnirsen, with peak sales forecasts of over $3 billion and $2 billion, respectively. The companys financials are solid, with $1.9 billion in cash and improved operating losses. Ionis is also making progress in their pipeline, with partner wins like epiravirsen for hepatitis B and heart trials in the works. Overall, Ionis is becoming a commercial powerhouse, turning scientific advancements into patient and shareholder successes. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/581eef0beeb7d406